Oculis Treats First Patient in Optic Neuritis Trial; Shares Up Pre-Bell
MT Newswires Live
Yesterday
Oculis (OCS) treated the first patient in a trial of Privosegtor to treat optic neuritis, the company said Monday.
The study's primary endpoint is the proportion of patients achieving at least a 15-letter gain from baseline, while the secondary endpoint is the mean change in low-contrast visual acuity after three months.
Optic neuritis is a rare condition characterized by an inflammation of the optic nerve that can result in visual impairment and is often the first sign of multiple sclerosis.
Oculis plans an investigational new drug submission for Privosegtor to treat acute multiple sclerosis relapses in Q4, it said.
The company's shares were up 4.6% in premarket activity.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.